Search results for " RBV"

showing 5 items of 5 documents

The role of internal resources in the competitive positioning of Sicilian wine cooperatives

2019

The paper is an original article that uses accounting frameworks to determine what creates a competitive advantage in a cooperative business model. In particular, it investigates the influence of tangible, intangible and financial resources on the business performance of cooperatives operating in the Sicilian wine industry, with the RBV of the firms as a theoretical background. Using a linear regression model, our results show that tangible and financial resources are a source of a sustained competitive advantage. This study fills the gap existing in the strategic management literature related to the role of resources, tangible and intangible, in the cooperative system, providing both theor…

Wine0303 health sciencesInformation Systems and Management030309 nutrition & dietetics010501 environmental sciencesManagement Science and Operations ResearchBusiness modelCompetitive advantage Econometric model Intangible resources RBV Resource-based view Tangible resources Wine industry01 natural sciencesCompetitive advantagelanguage.human_language03 medical and health sciencesEconometric modelSettore AGR/01 - Economia Ed Estimo RuraleResource-based viewlanguageStrategic managementBusinessBusiness and International ManagementSicilianIndustrial organization0105 earth and related environmental sciencesWine industryInternational Journal of Globalisation and Small Business
researchProduct

Wykorzystanie zasobowej teorii organizacji w zarządzaniu szpitalami publicznymi

2017

Podejście zasobowe do organizacji (Resource-based View - RBV) zostało spopularyzowane na początku lat 90. ubiegłego stulecia. Jednocześnie w dalszym ciągu obserwuje się proces kształtowania zasobowej teorii organizacji (Resource- -based Theory - RBT). Rosnąca konkurencja wśród podmiotów ochrony zdrowia stanowi przesłankę do wykorzystania założeń RBT w zarządzaniu nimi. Placówki te stają przed koniecznością ciągłej adaptacji do pojawiających się wyzwań, co wydaje się szczególnie trudne dla szpitali publicznych. Ich sukces zależy od posiadania odpowiednich zasobów, kluczowych kompetencji, dynamicznych zdolności, umiejętności uczenia się oraz przewidywania przyszłości, w odpowiedni sposób się …

zasobowe podejście (Resource-based View - RBV)resource-based view (RBV)resource-based theory (RBT).zasobowa teoria (Resource-based Theory - RBT)public hospitalszpital publicznyHandel Wewnętrzny
researchProduct

Risk of disease decompensation and HCC in patients with HCV cirrhosis non responders to PEG IFN plus RBV

2012

HCV HCC PEG IFN RBV
researchProduct

Cost effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

2013

Background & Aims Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC. Methods The available published literature provided the data source. The target population was made up of previously treated Caucasian patients with G1 CHC and these were evaluated over a lifetime horizo…

MaleTVRCost effectivenessCost-Benefit AnalysisPIPeginterferon-alfaBOCHepacivirusBOC Boceprevir CHC Cost-effectiveness DT G1 ICER NR PAR PI PegIFN RBV RR TVR Telaprevir boceprevir chronic hepatitis C dual therapy genotype 1 incremental cost-effectiveness ratio non-response partial response pegylated interferon protease inhibitors relapse ribavirin telaprevirTelaprevirTelaprevirchemistry.chemical_compoundPegylated interferonnon-responseboceprevirincremental cost-effectiveness ratioRBVTreatment FailureDThealth care economics and organizationsRandomized Controlled Trials as Topicrelapsecost effectivenessICERMiddle AgedMarkov ChainsModels EconomicItalyQuality-Adjusted Life YearsSettore SECS-P/02 - politica economicaSettore SECS-S/01 - StatisticaIncremental cost-effectiveness ratioOligopeptidesmedicine.drugmedicine.medical_specialtyGenotypeProlineribavirinSettore MED/12 - GASTROENTEROLOGIAprotease inhibitorsNRRRAntiviral AgentsInternal medicineBoceprevirG1medicineHumanschronic hepatitis Cpegylated interferongenotype 1Hepatologybusiness.industryRibavirindual therapyHepatitis C ChronicQuality-adjusted life yearSurgeryCHCPegIFNchemistryCost-effectivenesspartial responsebusinessPAR
researchProduct

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with…

2017

Summary Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), …

CyclopropanesCompassionate Use TrialsLiver CirrhosisMalechemistry.chemical_compound0302 clinical medicine2-NaphthylamineHCV direct-acting antiviral mixed cryoglobulinemia RBVAnilides030212 general & internal medicineLongitudinal StudiesProspective StudiesChronicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; UracilSettore MED/12 - GastroenterologiaSulfonamidesDasabuvirHCV DAAGastroenterologyvirus diseasesValineMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CTreatment OutcomeGastroenterology; HepatologyCombinationDrug Therapy Combination030211 gastroenterology & hepatologyFemalemedicine.drugAdultmedicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Hepatology; GastroenterologyHepatitis C virus genotype 1 Hepatitis C virus genotype 4 decompensated liver cirrhosis antiviral therapy dasabuvir ombitasvir paritaprevirHepatology; GastroenterologyAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinmedicineHumansDecompensationAdverse effectUracilAgedRitonavirHepatologybusiness.industryRibavirinHepatitis C ChronicVirologyOmbitasvirClinical trialchemistryParitaprevirRitonavirCarbamatesbusiness
researchProduct